|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Whereas, the KRAS mutation p.Gly13Asp have been detected only in MSI-H. 43.75 % of the patients harboured combined mutations in KRAS and TP53 genes and the tumor of 71.42 % of them showed TP53 overexpression.
|
24078161 |
2013 |
|
Hematologic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
|
Autoimmune Lymphoproliferative Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
|
Adenocarcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We report here two cases of ALK-rearranged adenocarcinomas harboring concomitant exon 2 K-RAS mutations (G13D and Q61H).
|
26898615 |
2016 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We have investigated Ca(2+) signalling in two human colorectal cancer cell lines and their isogenic derivatives in which the allele encoding oncogenic K-Ras (G13D) was deleted by homologous recombination.
|
24522186 |
2014 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
We have investigated Ca(2+) signalling in two human colorectal cancer cell lines and their isogenic derivatives in which the allele encoding oncogenic K-Ras (G13D) was deleted by homologous recombination.
|
24522186 |
2014 |
|
Hypoglycemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found K-ras(G13D) mutation to occur at far greater incidence in cells derived from xenografted tumors or exposed to conditions of combined hypoxia and hypoglycemia in vitro.
|
16166287 |
2005 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found K-ras(G13D) mutation to occur at far greater incidence in cells derived from xenografted tumors or exposed to conditions of combined hypoxia and hypoglycemia in vitro.
|
16166287 |
2005 |
|
Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
We examined the anti-proliferative effect of miR-143#12 and the mechanism in human colon cancer DLD-1 cell (G13D) and other cell types harboring K-Ras mutations.
|
29498789 |
2018 |
|
Colon Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
We examined the anti-proliferative effect of miR-143#12 and the mechanism in human colon cancer DLD-1 cell (G13D) and other cell types harboring K-Ras mutations.
|
29498789 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate whether the efficacy of anti-EGFR mAbs for mCRC differs between tumours harbouring a KRAS G13D mutation (KRAS G13D) and KRAS mutations other than G13D (other KRAS MT).
|
26812186 |
2016 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to study proliferation and survival effects induced by BRAF inhibition in MSI CRC cell lines harbouring distinct genetic backgrounds (BRAF V600E or KRAS G13D).
|
18098337 |
2008 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
To accomplish this, we first carried out an in silico analysis of RNA-seq databases and found that the distribution of alternative splicing isoforms of genes RPL13, HSP90B1, ENO1, EPDR1 and ZNF518B was altered in human CRC cell lines carrying the G13D KRAS mutation when compared to cell lines carrying wild-type KRAS.
|
27805251 |
2016 |
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Thus, a mutation frequency of 40% and a cluster of three mutation types (p.G12D, pG12V, and p.G13D) in primaries and metastases can be defined as benchmarks for routine KRAS analyses.
|
19679400 |
2009 |
|
Secondary Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Thus, a mutation frequency of 40% and a cluster of three mutation types (p.G12D, pG12V, and p.G13D) in primaries and metastases can be defined as benchmarks for routine KRAS analyses.
|
19679400 |
2009 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This unique trial will yield prospective information on the efficacy of cetuximab and whether this is further enhanced with chemotherapy in two distinct populations of patients with metastatic colorectal cancer: the "quadruple wild type", which may 'superselect' for tumours sensitive to EGFR-inhibition, and the rare KRAS G13D mutated tumours, which are also postulated to be sensitive to the drug.
|
27246726 |
2016 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
This retrospective pooled analysis suggests comparable efficacy of cetuximab-based and bevacizumab-based first-line therapy in patients with p.G13D mutant mCRC.
|
22441566 |
2012 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
This meta-analysis demonstrates no significant difference between KRAS G13D and other KRAS MT tumours in terms of treatment benefit from anti-EGFR mAbs for mCRC.
|
26812186 |
2016 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results reveal that KRAS G13D is responsive to neurofibromin-stimulated hydrolysis and suggest that a subset of <i>KRAS</i> G13-mutated colorectal cancers that are neurofibromin-competent may respond to EGFR therapies.
|
31611389 |
2019 |
|
Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
|
Colon Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
|
melanoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |